全文获取类型
收费全文 | 323814篇 |
免费 | 22623篇 |
国内免费 | 1228篇 |
专业分类
耳鼻咽喉 | 3513篇 |
儿科学 | 8884篇 |
妇产科学 | 6254篇 |
基础医学 | 42295篇 |
口腔科学 | 6615篇 |
临床医学 | 31372篇 |
内科学 | 68432篇 |
皮肤病学 | 4167篇 |
神经病学 | 31323篇 |
特种医学 | 10506篇 |
外国民族医学 | 14篇 |
外科学 | 49068篇 |
综合类 | 4946篇 |
现状与发展 | 3篇 |
一般理论 | 439篇 |
预防医学 | 29048篇 |
眼科学 | 7515篇 |
药学 | 22413篇 |
2篇 | |
中国医学 | 633篇 |
肿瘤学 | 20223篇 |
出版年
2023年 | 1398篇 |
2022年 | 2403篇 |
2021年 | 5622篇 |
2020年 | 3400篇 |
2019年 | 5592篇 |
2018年 | 6568篇 |
2017年 | 5087篇 |
2016年 | 5630篇 |
2015年 | 6583篇 |
2014年 | 9734篇 |
2013年 | 13999篇 |
2012年 | 20830篇 |
2011年 | 22619篇 |
2010年 | 12636篇 |
2009年 | 11566篇 |
2008年 | 20978篇 |
2007年 | 22225篇 |
2006年 | 21346篇 |
2005年 | 21782篇 |
2004年 | 20805篇 |
2003年 | 19352篇 |
2002年 | 18690篇 |
2001年 | 3000篇 |
2000年 | 2300篇 |
1999年 | 3191篇 |
1998年 | 4157篇 |
1997年 | 3558篇 |
1996年 | 3065篇 |
1995年 | 2828篇 |
1994年 | 2490篇 |
1993年 | 2383篇 |
1992年 | 1836篇 |
1991年 | 1713篇 |
1990年 | 1558篇 |
1989年 | 1434篇 |
1988年 | 1487篇 |
1987年 | 1472篇 |
1986年 | 1388篇 |
1985年 | 1556篇 |
1984年 | 2006篇 |
1983年 | 1944篇 |
1982年 | 2457篇 |
1981年 | 2196篇 |
1980年 | 2041篇 |
1979年 | 1163篇 |
1978年 | 1281篇 |
1977年 | 1250篇 |
1976年 | 1102篇 |
1975年 | 939篇 |
1974年 | 927篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
101.
102.
103.
104.
105.
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. 总被引:11,自引:0,他引:11
Fairooz F Kabbinavar Joseph Schulz Michael McCleod Taral Patel John T Hamm J Randolph Hecht Robert Mass Brent Perrou Betty Nelson William F Novotny 《Journal of clinical oncology》2005,23(16):3697-3705
PURPOSE: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC). This randomized, phase II trial compared bevacizumab plus fluorouracil and leucovorin (FU/LV) versus placebo plus FU/LV as first-line therapy in patients considered nonoptimal candidates for first-line irinotecan. PATIENTS AND METHODS: Patients had metastatic CRC and one of the following characteristics: age > or = 65 years, Eastern Cooperative Oncology Group performance status 1 or 2, serum albumin < or = 3.5 g/dL, or prior abdominal/pelvic radiotherapy. Patients were randomly assigned to FU/LV/placebo (n = 105) or FU/LV/bevacizumab (n = 104). The primary end point was overall survival. Secondary end points were progression-free survival, response rate, response duration, and quality of life. Safety was also assessed. RESULTS: Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16). Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo); hazard ratio was 0.50; P = .0002. Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055); duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo); hazard ratio was 0.42; P = .088. Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%) but was controlled with oral medication and did not cause study drug discontinuation. CONCLUSION: Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival. 相似文献
106.
107.
Andrew J Montgomery Kris Thielemans Mitul A Mehta Federico Turkheimer Sanida Mustafovic Paul M Grasby 《Journal of nuclear medicine》2006,47(12):1936-1944
Head movement presents a continuing problem in PET studies. Head restraint minimizes movement but is unreliable, resulting in the need to develop alternative strategies. These include frame-by-frame (FBF) realignment or use of motion tracking (MT) during the scan to realign PET acquisition data. Here we present a comparative analysis of these 2 methods of motion correction. METHODS: Eight volunteers were examined at rest using (11)C-raclopride PET with the radioligand administered as a bolus followed by constant infusion to achieve steady state. Binding potential (BP) was estimated using the ratio method during 2 periods of the scan at steady state. Head movement was compensated by using coregistration between frames (FBF) and 3 methods using MT measurements of head position acquired with a commercially available optical tracking system. RESULTS: All methods of realignment improved test-retest reliability and noise characteristics of the raw data, with important consequences for the power to detect small changes in radiotracer binding, and the potential to reduce false-positive and false-negative results. MT methods were superior to FBF realignment using coregistration on some indices. CONCLUSION: Such methods have considerable potential to improve the reliability of PET data with important implications for the numbers of volunteers required to test hypotheses. 相似文献
108.
Background
Cerebral arterial gas embolism is a potentially life-threatening event. Intraarterial air can occlude blood flow directly or cause thrombosis. Sclerotherapy is an extremely rare cause of cerebral arterial gas embolism. 相似文献109.
Anthony P. Belanger John F. Byrne Justin M. Paolino Timothy R. DeGrado 《Nuclear medicine and biology》2009,36(8):955-959
The bubble point test is the de facto standard for postproduction filter membrane integrity test in the radiopharmaceutical community. However, the bubble point test depends on a subjective visual assessment of bubbling rate that can be obscured by significant diffusive gas flows below the manufacturer's prescribed bubble point. To provide a more objective means to assess filter membrane integrity, this study evaluates the pressure-hold test as an alternative to the bubble point test. In our application of the pressure-hold test, the nonsterile side of the sterilizing filter is pressurized to 85% of the predetermined bubble point with nitrogen, the filter system is closed off from the pressurizing gas and the pressure is monitored over a prescribed time interval. The drop in pressure, which has a known relationship with diffusive gas flow, is used as a quantitative measure of membrane integrity. Characterization of the gas flow vs. pressure relationship of each filter/solution combination provides an objective and quantitative means for defining a critical value of pressure drop over which the membrane is indicated to be nonintegral. The method is applied to sterilizing filter integrity testing associated with the commonly produced radiopharmaceuticals, [18F]FDG and [11C]PIB. The method is shown to be robust, practical and amenable to automation in radiopharmaceutical manufacturing environments (e.g., hot cells). 相似文献
110.